A股異動丨未名醫藥漲5.63% 前三季度淨利同比預增233%-350%
格隆匯10月24日丨未名醫藥(002581.SZ)漲5.63%,報7.51元,成交8971萬元,總市值49.5億元。

未名醫藥昨日晚間披露業績預告,公司預計前三季度實現淨利潤4192.14萬-5671.72萬元,同比增長232.90%-350.39%。日前,公司收到參股公司北京科興三季度財務報表,致使公司業績變動達到業績預告披露要求,導致業績預告延遲。由於北京科興與公司控股股東之間的矛盾,北京科興向公司提供財務報表的時間存在不確定性,由此或將造成公司業績預告與更正公告延遲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.